CMS Seeks Input on Contractor to Prevent 340B, Medicare Maximum Price Duplication

Kelsey Lang Avalere
Kelsey Lang, a health policy principal at Avalere, said CMS's request for information affirms its interest in preventing 340B duplicate discounts.
Regulators are seeking input on a contractor to help it shield drug manufacturers from giving duplicate 340B discounts and new [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

5 Best Practices for Running and Optimizing a Mixed-Use Program

SPONSORED CONTENT

To ensure compliance, maximize savings, and streamline operations, consider these five best practices.

1. Proficiency in Data Management

To effectively manage your 340B program, it’s crucial to comprehend how data is created, stored, and transmitted to your Third-Party Administrator (TPA). Typically,

Read More »

Teva Adds Drug to Hospital Contract Pharmacy Restriction Policy

Drugmaker Teva recently added its medication Austedo to its list of drugs under 340B contract pharmacy restrictions for hospitals.
Drug manufacturer Teva this week added a drug to the hospital contract pharmacy restrictions it first implemented in June. The [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Congressional Witnesses Urge Medicare 340B Cuts

Dr. Debra Patt, executive vice president at Texas Oncology, testified during a House subcommittee hearing that the 340B program was "broken."
Witnesses recently told a U.S. House subcommittee that Congress should cut Medicare payments for 340B drugs. The House Energy and [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

News Alert

340B Dispute Resolution Final Rule Enters Last Stage of Regulatory Review

HHS signage and building
HRSA plans to host a webinar for federal grantees in the days leading up to the 2024 340B recertification period.
A final rule to implement the 340B administrative dispute resolution (ADR) process arrived this week at the last stage of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Five More Providers Owe Drugmakers 340B Repayment: Audits

HRSA building and signage
HRSA confirmed it will end a pandemic-era waiver program that allowed 340B drug use in certain offsite hospital locations.
A total of 16 covered entities (CEs) owe repayment to drugmakers, five more than reported a month ago, according to [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Rural Providers Urge Congress to Extend Pandemic-Era 340B Eligibility Exemptions

Tidelands Georgetown Memorial Hospital is part of a coalition of rural providers pushing Congress to extend a 2022 340B eligibility waiver.
More than 400 hospitals risk losing 340B eligibility if Congress does not extend exemptions authorized during the public health emergency [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

10 Questions to Ask Your 340B TPA about Your Contract and Fees

Holly Russo, Maxor 340B

SPONSORED CONTENT

If you have one or more agreements with 340B Third Party Administrator(s) (TPA) to manage your contract pharmacy arrangements, how much do you know about those contracts and associated fees?  Chances are, you don’t know the answers to all the questions that follow.  Be

Read More »

Most 340B DSH Hospitals Provide Below-Average Charity Care, Says Analysis Backed by Critics

Bob Dold, a spokesperson for AIR340B, said the 340B program "has not translated into a stronger safety-net” after a drug industry backed analysis found 340B DSH hospitals provide below-average charity care.
The majority of 340B disproportionate share hospitals (DSH) provide charity care at lower rates than the national hospital average, found [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Paper Warns on Duplicate Discounts from 340B Ceiling Price, Medicare Maximum Price

An Avalere study suggested 340B duplicate discounts could increase as a result of Medicare drug price negotiations.
Timelines for manufacturers to provide new Medicare “maximum fair prices” (MFPs) and 340B ceiling prices on drugs are misaligned, risking [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live